SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yijun Zhang, Yongmei Zhang, Yaoyue Kang, Jinyu Wang, Hongyan Liu, Haoxiang Zhu, Yanli Qin, Richeng Mao, Xu Lin, Mengji Lu, Jiming Zhang, Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus, Journal of Virological Methods, 2014, 201, 51

    CrossRef

  2. 2
    William E. Delaney, Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome, Antiviral Research, 2013, 99, 1, 34

    CrossRef

  3. 3
    Wen Xie, Guangfeng Shi, Hongfei Zhang, Guiming Zhao, Zujiang Yu, Zhenwei Lang, Hong Zhao, Jie Yan, Jun Cheng, A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol, Hepatology International, 2012, 6, 2, 441

    CrossRef

  4. 4
    Eleftherios Michailidis, Karen A. Kirby, Atsuko Hachiya, Wangdon Yoo, Sun Pyo Hong, Soo-Ok Kim, William R. Folk, Stefan G. Sarafianos, Antiviral therapies: Focus on hepatitis B reverse transcriptase, The International Journal of Biochemistry & Cell Biology, 2012, 44, 7, 1060

    CrossRef

  5. 5
    Yu-Bing Zhou, Ya-Feng Wang, Yan Zhang, Li-Yun Zheng, Xiao-Ang Yang, Ning Wang, Jin-Hua Jiang, Fang Ma, De-Tao Yin, Chang-Yu Sun, Qing-Duan Wang, In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates, European Journal of Pharmacology, 2012, 683, 1-3, 10

    CrossRef

  6. 6
    Cheng Wang, Rong Fan, Jian Sun, Jinlin Hou, Prevention and management of drug resistant hepatitis B virus infections, Journal of Gastroenterology and Hepatology, 2012, 27, 9
  7. 7
    Yoon-Seon Lee, Young-Hwa Chung, Jeong A Kim, Young Joo Jin, Won Hyung Park, Sung Eun Kim, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young Suk Lim, Han Chu Lee, Yung Sang Lee, Dong Jin Suh, rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy, Journal of Gastroenterology and Hepatology, 2012, 27, 2
  8. 8
    Hong J. Kim, Jung H. Park, Dong I. Park, Yong K. Cho, Chong I. Sohn, Woo K. Jeon, Byung I. Kim, The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment, Liver International, 2012, 32, 2
  9. 9
    Balint Stewart, Modou L Jobarteh, Ramu Sarge-Njie, Abraham Alabi, Thushan de Silva, Kevin Peterson, Ingrid Peterson, Hilton Whittle, Sarah Rowland-Jones, Assan Jaye, Matthew Cotten, Maimuna Mendy, Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa, BMC Research Notes, 2011, 4, 1, 561

    CrossRef

  10. 10
    J. Inoue, Y. Ueno, Y. Wakui, H. Niitsuma, K. Fukushima, Y. Yamagiwa, M. Shiina, Y. Kondo, E. Kakazu, K. Tamai, N. Obara, T. Iwasaki, T. Shimosegawa, Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern, Journal of Viral Hepatitis, 2011, 18, 3
  11. 11
    Lihui Deng, Hong Tang, Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites, Hepatology Research, 2011, 41, 11
  12. 12
    Shuang Wu, Kenichi Fukai, Fumio Imazeki, Makoto Arai, Tatsuo Kanda, Yutaka Yonemitsu, Osamu Yokosuka, Initial Virological Response and Viral Mutation with Adefovir Dipivoxil Added to Ongoing Lamivudine Therapy in Lamivudine-Resistant Chronic Hepatitis B, Digestive Diseases and Sciences, 2011, 56, 4, 1207

    CrossRef

  13. 13
    J. W. Park, H. S. Kim, D. D. Seo, J. S. Jang, W. G. Shin, K. H. Kim, M. K. Jang, J. H. Lee, H. Y. Kim, D. J. Kim, M. S. Lee, C. K. Park, Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance, Journal of Viral Hepatitis, 2011, 18, 10
  14. 14
    S. Saab, S. Desai, D. Tsaoi, F. Durazo, S. Han, A. McClune, C. Holt, D. Farmer, L. Goldstein, R. W. Busuttil, Posttransplantation Hepatitis B Prophylaxis with Combination Oral Nucleoside and Nucleotide Analog Therapy, American Journal of Transplantation, 2011, 11, 3
  15. 15
    Kentaro Matsuura, Yasuhito Tanaka, Atsunori Kusakabe, Shuhei Hige, Jun Inoue, Masashi Komatsu, Tomoyuki Kuramitsu, Katsuharu Hirano, Tomoyoshi Ohno, Izumi Hasegawa, Haruhiko Kobashi, Keisuke Hino, Yoichi Hiasa, Hideyuki Nomura, Fuminaka Sugauchi, Shunsuke Nojiri, Takashi Joh, Masashi Mizokami, Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial, Hepatology Research, 2011, 41, 6
  16. 16
    Mathieu Daudé, Lionel Rostaing, Karine Sauné, Laurence Lavayssière, Grégoire Basse, Laure Esposito, Joelle Guitard, Jacques Izopet, Laurent Alric, Nassim Kamar, Tenofovir Therapy in Hepatitis B Virus-Positive Solid-Organ Transplant Recipients, Transplantation, 2011, 91, 8, 916

    CrossRef

  17. 17
    Choong Keun Cha, Hyeok Choon Kwon, Jae Youn Cheong, Sung Won Cho, Sun Pyo Hong, Soo-Ok Kim, Wang Don Yoo, Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B, Journal of Medical Virology, 2009, 81, 3
  18. 18
    David M Iser, Sharon R Lewin, Future directions in the treatment of HIV–HBV coinfection, HIV Therapy, 2009, 3, 4, 405

    CrossRef

  19. 19
    Pietro Lampertico, Alessio Aghemo, Mauro Viganò, Massimo Colombo, HBV and HCV Therapy, Viruses, 2009, 1, 3, 484

    CrossRef

  20. 20
    Yoon-Seon Lee, Young-Hwa Chung, Jeong A. Kim, Sung Eun Kim, Jung Woo Shin, Kang Mo Kim, Young-Suk Lim, Neung Hwa Park, Han Chu Lee, Yung Sang Lee, Dong Jin Suh, Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy, Liver International, 2009, 29, 4
  21. 21
    Nao Kurashige, Kazuyoshi Ohkawa, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Tsugiko Oze, Shinichi Kiso, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Yoshinori Doi, Akira Yamada, Kazuto Fukuda, Masahide Oshita, Eiji Mita, Hiroyuki Fukui, Toshihiko Nagase, Harumasa Yoshihara, Yasuharu Imai, Michio Kato, Takeshi Kashihara, Norio Hayashi, Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance, Journal of Gastroenterology, 2009, 44, 8, 864

    CrossRef

  22. 22
    Maria Seifer, April Patty, Ilaria Serra, Bin Li, David N. Standring, Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir, Antiviral Research, 2009, 81, 2, 147

    CrossRef

  23. 23
    Zhang Xing-guo, Miao Jing, Li Min-wei, Jiang Sai-ping, Hu Fu-qiang, Du Yong-zhong, Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy, Journal of Zhejiang University SCIENCE B, 2008, 9, 6, 506

    CrossRef

  24. 24
    Kazuyoshi Ohkawa, Tetsuo Takehara, Michio Kato, Matsuo Deguchi, Masanori Kagita, Hayato Hikita, Akira Sasakawa, Keisuke Kohga, Akio Uemura, Ryotaro Sakamori, Shinjiro Yamaguchi, Takuya Miyagi, Hisashi Ishida, Tomohide Tatsumi, Norio Hayashi, Supportive Role Played by Precore and PreS2 Genomic Changes in the Establishment of Lamivudine-Resistant Hepatitis B Virus, The Journal of Infectious Diseases, 2008, 198, 8, 1150

    CrossRef

  25. 25
    Jae Hyeon Moon, Mong Cho, Ki Tae Yoon, Jung Ho Bae, Jeong Heo, Gwang Ha Kim, Dae Hwan Kang, Geun Am Song, The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection, The Korean Journal of Hepatology, 2008, 14, 4, 503

    CrossRef

  26. 26
    Irene Rapti, Evangelini Dimou, Panayota Mitsoula, Stephanos J. Hadziyannis, Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B, Hepatology, 2007, 45, 2
  27. 27
    Guy W. Neff, Nyingi Kemmer, Tiffany E. Kaiser, Victoria C. Zacharias, Michele Alonzo, Mark Thomas, Joseph Buell, Combination Therapy in Liver Transplant Recipients with Hepatitis B Virus Without Hepatitis B Immune Globulin, Digestive Diseases and Sciences, 2007, 52, 10, 2497

    CrossRef

  28. 28
    R. Bárcena Marugán, Adefovir en el tratamiento de la infección por virus B, Gastroenterología y Hepatología, 2006, 29, 36

    CrossRef

  29. 29
    Tim Shaw, Angeline Bartholomeusz, Stephen Locarnini, HBV drug resistance: Mechanisms, detection and interpretation, Journal of Hepatology, 2006, 44, 3, 593

    CrossRef

  30. 30
    A. Potthoff, H. L. Tillmann, C. Bara, K. Deterding, K. Pethig, S. Meyer, A. Haverich, K. H. W. Böker, M. P. Manns, H. Wedemeyer, Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy, Journal of Viral Hepatitis, 2006, 13, 11
  31. 31
    Marc Bourlière, Perspectives et stratégies futures dans la prise en charge de la résistance aux analogues antiviraux dans le traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2006, 30, 10, 34

    CrossRef

  32. 32
    Necati Çakir, Ömer Nuri Pamuk, Hasan Ümit, Kenan Midilli, Successful Treatment with Adefovir of One Patient Whose Cryoglobulinemic Vasculitis Relapsed under Lamivudine Therapy and Who was Diagnosed to Have HBV Virologic Breakthrough with YMDD Mutations, Internal Medicine, 2006, 45, 21, 1213

    CrossRef

  33. 33
    Florian van Bömmel, Bernhard Zöllner, Christoph Sarrazin, Ulrich Spengler, Dietrich Hüppe, Bernd Möller, Heinz-Hubert Feucht, Bertram Wiedenmann, Thomas Berg, Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy, Hepatology, 2006, 44, 2
  34. 34
    Vincent Thibault, Where does adefovir stand amongst newly developed antivirals: from pharmacology to virology, Future Virology, 2006, 1, 5, 553

    CrossRef

  35. 35
    Richard L. Mackman, Tomas Cihlar, Acyclic and Cyclic Nucleoside Phosphonates,